Published in Rev Panam Salud Publica on May 01, 1997
Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191 | NCT01086709
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst (2010) 3.95
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst (2008) 3.32
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine (2008) 3.17
Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ (2009) 2.68
Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol (1998) 2.21
Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ (2000) 2.12
Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med (2005) 2.06
High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer (2007) 2.06
The oral cavity contains abundant known and novel human papillomaviruses from the Betapapillomavirus and Gammapapillomavirus genera. J Infect Dis (2011) 1.87
A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res (2010) 1.82
Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer (2003) 1.55
HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer (2001) 1.52
Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int J Cancer (2012) 1.44
Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog (2008) 1.44
Common genetic variants and risk for HPV persistence and progression to cervical cancer. PLoS One (2010) 1.43
Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica. Br J Cancer (2004) 1.40
Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst (2012) 1.40
Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years. Cancer Epidemiol Biomarkers Prev (2010) 1.36
Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis (2009) 1.35
Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions. Clin Diagn Lab Immunol (2004) 1.27
Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica. J Infect Dis (2011) 1.25
Sequence imputation of HPV16 genomes for genetic association studies. PLoS One (2011) 1.20
Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women. Cancer Epidemiol Biomarkers Prev (2009) 1.18
Collection of cervical secretions does not adversely affect Pap smears taken immediately afterward. Clin Diagn Lab Immunol (1998) 1.14
The cervical microbiome over 7 years and a comparison of methodologies for its characterization. PLoS One (2012) 1.11
Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort. J Natl Cancer Inst (2010) 1.09
Correlates of IL-10 and IL-12 concentrations in cervical secretions. J Clin Immunol (2003) 1.06
Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithelial neoplasia grade 2/3. Int J Cancer (2012) 1.03
Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection. Cancer Epidemiol Biomarkers Prev (2010) 1.02
Factors associated with fluctuations in IgA and IgG levels at the cervix during the menstrual cycle. J Infect Dis (2009) 1.00
Lactobacillus crispatus dominant vaginal microbiome is associated with inhibitory activity of female genital tract secretions against Escherichia coli. PLoS One (2014) 0.95
Persistence of concurrent infections with multiple human papillomavirus types: a population-based cohort study. J Infect Dis (2011) 0.95
Prevalence of infection with carcinogenic human papillomavirus among older women. CMAJ (2002) 0.95
Evaluation of a novel PCR-based assay for detection and identification of Chlamydia trachomatis serovars in cervical specimens. J Clin Microbiol (2007) 0.95
Content-Based Image Retrieval in Medicine: Retrospective Assessment, State of the Art, and Future Directions. Int J Healthc Inf Syst Inform (2009) 0.94
Single nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancer. PLoS One (2012) 0.93
A case-control study of endogenous hormones and cervical cancer. Br J Cancer (2004) 0.93
A population based study of herpes simplex virus 2 seroprevalence in rural Costa Rica. Sex Transm Infect (2003) 0.92
Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer. J Infect Dis (2011) 0.92
Investigating CBIR techniques for cervicographic images. AMIA Annu Symp Proc (2007) 0.91
Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. Int J Cancer (2009) 0.90
A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. BMC Infect Dis (2012) 0.90
Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection. Cytokine (2010) 0.90
Genetic admixture and population substructure in Guanacaste Costa Rica. PLoS One (2010) 0.88
Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited. Cancer Epidemiol Biomarkers Prev (2009) 0.88
Treatability by cryotherapy in a screen-and-treat strategy. J Low Genit Tract Dis (2009) 0.88
Precursors in cancer epidemiology: aligning definition and function. Cancer Epidemiol Biomarkers Prev (2013) 0.87
Evaluation of the FTA carrier device for human papillomavirus testing in developing countries. J Clin Microbiol (2012) 0.86
Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. Int J Cancer (2011) 0.85
An evaluation by midwives and gynecologists of treatability of cervical lesions by cryotherapy among human papillomavirus-positive women. Int J Gynecol Cancer (2009) 0.85
Balancing the Role of Priors in Multi-Observer Segmentation Evaluation. J Signal Process Syst (2008) 0.85
Can tissue-based immune markers be used for studying the natural history of cancer? Ann Epidemiol (2012) 0.83
Determinants and correlation of systemic and cervical concentrations of total IgA and IgG. Cancer Epidemiol Biomarkers Prev (2009) 0.83
Alterations of T-cell surface markers in older women with persistent human papillomavirus infection. Int J Cancer (2011) 0.79
Human papillomavirus infections in primary care. Clin Med Res (2007) 0.78
Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy. Int J Cancer (2011) 0.78
Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels. Front Oncol (2012) 0.78
Lack of heterogeneity of HPV16 E7 sequence compared with HPV31 and HPV73 may be related to its unique carcinogenic properties. Arch Virol (2010) 0.78
Longitudinal analysis of carcinogenic human papillomavirus infection and associated cytologic abnormalities in the Guanacaste natural history study: looking ahead to cotesting. J Infect Dis (2011) 0.77
Distinct Ecological Niche of Anal, Oral, and Cervical Mucosal Microbiomes in Adolescent Women. Yale J Biol Med (2016) 0.75
Multi-feature based Benchmark for Cervical Dysplasia Classification Evaluation. Pattern Recognit (2016) 0.75
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (1989) 19.87
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst (1995) 18.86
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96
Improved amplification of genital human papillomaviruses. J Clin Microbiol (2000) 11.50
Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol (1985) 11.38
Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst (1993) 9.48
Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis (1994) 7.00
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med (1999) 6.92
Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol (1986) 6.88
Residential exposure to magnetic fields and acute lymphoblastic leukemia in children. N Engl J Med (1997) 6.72
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst (1995) 5.35
Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med (1996) 5.14
Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst (1993) 5.07
Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med (1998) 4.65
Does nondifferential misclassification of exposure always bias a true effect toward the null value? Am J Epidemiol (1990) 4.63
HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA (2000) 4.62
Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst (1991) 4.14
Characteristics of women with dysplasia or carcinoma in situ of the cervix uteri. Br J Cancer (1980) 4.11
Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst (2000) 3.81
Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet (1998) 3.61
Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine--National Cancer Institute Benzene Study Group. J Natl Cancer Inst (1997) 3.61
Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol (1995) 3.59
Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev (2001) 3.43
Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol Biomarkers Prev (2001) 3.40
Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA (1999) 3.37
Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer (1993) 3.33
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Determination of left ventricular volumes by ultrasound. Circulation (1971) 3.09
Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst (1999) 2.98
Limitations of the case-only design for identifying gene-environment interactions. Am J Epidemiol (2001) 2.97
Human papillomavirus--the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer (1996) 2.91
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev (2001) 2.87
Recent advances in chemokines and chemokine receptors. Crit Rev Immunol (1999) 2.78
Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma. Urology (2009) 2.78
Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA (1994) 2.71
The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med (1984) 2.70
Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer (2006) 2.68
Random digit dialing in selecting a population-based control group. Am J Epidemiol (1984) 2.64
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer (2005) 2.62
Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer (2000) 2.62
A population-based case-control study of childhood leukemia in Shanghai. Cancer (1988) 2.59
Mammographic densities and risk of breast cancer. Cancer (1991) 2.47
Mesothelioma register 1967-68. Br J Ind Med (1974) 2.42
Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet (2000) 2.40
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev (2001) 2.38
Clinical and immunological responses to enzymes of Bacillus subtilis in factory workers and consumers. Clin Allergy (1973) 2.36
Controversy in primary care: Should asymptomatic haemochromatosis be treated? BMJ (2000) 2.36
A cell culture model of the blood-brain barrier. J Cell Biol (1991) 2.35
Association between childhood acute lymphoblastic leukemia and use of electrical appliances during pregnancy and childhood. Epidemiology (1998) 2.33
The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet (1998) 2.32
Characteristics of women with and without breast augmentation. JAMA (1997) 2.26
SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab (2006) 2.25
A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis (2000) 2.24
Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol (1998) 2.21
Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis (1995) 2.21
Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 alpha is mediated by the chemokine receptor CXCR4. Curr Biol (1998) 2.21
Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res (1990) 2.21
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
Saturated fat intake and lung cancer risk among nonsmoking women in Missouri. J Natl Cancer Inst (1993) 2.19
Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int (2002) 2.18
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Non-differential misclassification and bias towards the null: a clarification. Occup Environ Med (1995) 2.15
Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol (1995) 2.13
Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiol Biomarkers Prev (2001) 2.12
Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev (1997) 2.12
Survey of workers exposed to dusts containing derivatives of Bacillus subtilis. Br Med J (1970) 2.12
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 2.11
Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry (1998) 2.09
Assessment in the guinea-pig ileum and mouse vas deferens of benzomorphans which have strong antinociceptive activity but do not substitute for morphine in the dependent monkey. Br J Pharmacol (1975) 2.05
The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet (1999) 2.03
Geographic variation in mortality from breast cancer among white women in the United States. J Natl Cancer Inst (1995) 2.03
Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst (1985) 2.00